Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
53 hedge funds and large institutions have $17.8M invested in Melinta Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 15 closing their positions.
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
2% more funds holding
Funds holding: 52 → 53 (+1)
5% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $2.97M
4% less capital invested
Capital invested by funds: $18.6M → $17.8M (-$774K)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$830K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$545K |
| 3 |
SC
Sculptor Capital
New York
|
+$470K |
| 4 |
Renaissance Technologies
New York
|
+$442K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IP
Isthmus Partners
Madison,
Wisconsin
|
-$7.66M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.53M |
| 3 |
DM
Deerfield Management
New York
|
-$1.27M |
| 4 |
BlackRock
New York
|
-$1.19M |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$542K |
MLNT Hedge Fund Activity: Q2 2019 in Review
53 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q2 2019, worth a combined $17.8M — down 4.2% from $18.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MLNT positions and 15 closed out — a net gain of 2 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $830K. The largest seller was Isthmus Partners, exiting entirely with an estimated $7.66M sold.
- 53 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q2 2019, up from 52 in Q1 2019.
- Funds reported $17.8M of Melinta Therapeutics, Inc. Common Stock stock for Q2 2019, down 4.2% quarter-over-quarter.
- 17 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q2 2019 and 15 closed out, a net change of +2 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q2 2019 was Vanguard Group, an estimated $830K added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q2 2019 was Isthmus Partners, an estimated $7.66M sold.
Based on aggregated 13F filings for Q2 2019.